Strategic Advocates’s AbbVie ABBV Stock Holding History

Strategic Advocates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-31	Closed	-$6.74K	–	260
2026 Q1	$6.74K	Sell	31 -50	-62%	-$11.1K	0.03%	169
2025 Q4	$18.7K	Buy	81 +10	+14%	+$2.28K	﹤0.01%	296
2025 Q3	$16.5K	Buy	+71	New	+$14.5K	﹤0.01%	307

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Strategic Advocates's ABBV Position: Q2 2026 in Review

Strategic Advocates sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 31 shares — an estimated $6.74K sold.

Strategic Advocates first reported a position in ABBV in Q3 2025 and held it in 3 quarters. The position peaked at $18.7K in Q4 2025. 4,218 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Strategic Advocates reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
Strategic Advocates sold 31 AbbVie shares in Q2 2026, an estimated $6.74K.
Strategic Advocates first reported a position in AbbVie in Q3 2025 and held it in 3 quarters.
Strategic Advocates's AbbVie position peaked at $18.7K in Q4 2025.
4,218 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Strategic Advocates's 13F filing for Q2 2026, filed 13 Aug 2026.